Silica Nanoparticle as a Lymph Node Targeting Platform for Vaccine Delivery.

Nanoparticles have emerged as the platform of choice to improve the efficacy and safety of subunit vaccines. A major challenge underlying the use of nanomaterials in vaccines lies in the particle designs that can efficiently target and activate the antigen-presenting cells, especially dendritic cells. Here we show a toll-like receptor 9 (TLR-9) agonist and antigen coloaded, silica nanoparticles (SiNPs) are able to accumulate in antigen presenting cells in the draining lymph nodes after injection. Vaccine loaded SiNPs led to dramatically enhanced induction of antigen-specific B and T cell responses as compared to soluble vaccines, which in turn drove a protective antitumoral immunity in a murine tumor model. Additionally, SiNP vaccines greatly reduced the production of systemic proinflammatory cytokines and completely abrogated splenomegaly, key systemic toxicities of TLR-9 agonists that limit their advances in clinical applications. Our results demonstrate that structure-optimized silica nanocarriers can be used as an effective and safe platform for targeted delivery of subunit vaccines.

[1]  Seungpyo Hong,et al.  Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. , 2004, Bioconjugate chemistry.

[2]  D. Mancino,et al.  Adjuvant effects of amorphous silica and of aluminium hydroxide on IgE and IgG1 antibody production in different inbred mouse strains. , 1980, International archives of allergy and applied immunology.

[3]  S. Akira,et al.  Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity , 2004, Cancer Research.

[4]  E. Celis,et al.  Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  T. Ohno,et al.  Hollow Structure Improved Anti-Cancer Immunity of Mesoporous Silica Nanospheres In Vivo. , 2016, Small.

[6]  C. Melief,et al.  Vaccines for established cancer: overcoming the challenges posed by immune evasion , 2016, Nature Reviews Cancer.

[7]  Yeong‐Min Park,et al.  Multivalent Polymer Nanocomplex Targeting Endosomal Receptor of Immune Cells for Enhanced Antitumor and Systemic Memory Response. , 2015, Angewandte Chemie.

[8]  U. Yrlid,et al.  Lymph-borne CD 8 a þ dendritic cells are uniquely able to cross-prime CD 8 þ T cells with antigen acquired from intestinal epithelial cells , 2014 .

[9]  T. Scully.  The age of vaccines , 2014, Nature.

[10]  Jeffrey B Ulmer,et al.  Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.

[11]  Bali Pulendran,et al.  Immunological mechanisms of vaccination , 2011, Nature Immunology.

[12]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[13]  Yufang Zhu,et al.  Binding of CpG oligodeoxynucleotides to mesoporous silica nanoparticles for enhancing delivery efficiency , 2015 .

[14]  V. Appay,et al.  CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.

[15]  Rino Rappuoli,et al.  From empiricism to rational design: a personal perspective of the evolution of vaccine development , 2014, Nature Reviews Immunology.

[16]  G. Weiner,et al.  Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs1 , 2001, The Journal of Immunology.

[17]  S. Streatfield,et al.  Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development , 2012, Vaccine.

[18]  Younan Xia,et al.  Gold Nanomaterials at Work in Biomedicine. , 2015, Chemical reviews.

[19]  C. Mandl,et al.  Vaccines for the twenty-first century society , 2011, Nature Reviews Immunology.

[20]  Haipeng Liu,et al.  Guiding principles in the design of molecular bioconjugates for vaccine applications. , 2015, Bioconjugate chemistry.

[21]  I. Gursel,et al.  CpG ODN Nanorings Induce IFNα from Plasmacytoid Dendritic Cells and Demonstrate Potent Vaccine Adjuvant Activity , 2014, Science Translational Medicine.

[22]  Xin Du,et al.  Label-free dendrimer-like silica nanohybrids for traceable and controlled gene delivery. , 2014, Biomaterials.

[23]  J. DeSimone,et al.  Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity. , 2015, Molecular pharmaceutics.

[24]  Yuhua Wang,et al.  Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[25]  D. Irvine,et al.  Engineering New Approaches to Cancer Vaccines , 2015, Cancer Immunology Research.

[26]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[27]  D. Irvine,et al.  Synthetic Nanoparticles for Vaccines and Immunotherapy. , 2015, Chemical reviews.

[28]  S. Geary,et al.  Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN , 2011, Cancer Immunology, Immunotherapy.

[29]  Paula T Hammond,et al.  Implantable Silk Composite Microneedles for Programmable Vaccine Release Kinetics and Enhanced Immunogenicity in Transcutaneous Immunization , 2013, Advanced healthcare materials.

[30]  N. Glaichenhaus,et al.  Lymph Node Resident Rather Than Skin-Derived Dendritic Cells Initiate Specific T Cell Responses after Leishmania major Infection , 2006, The Journal of Immunology.

[31]  Seungpyo Hong,et al.  Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? , 2007, Accounts of chemical research.

[32]  S. Akira,et al.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.

[33]  V. Soumelis,et al.  Characterization of resident and migratory dendritic cells in human lymph nodes , 2012, The Journal of experimental medicine.

[34]  Chengzhong Yu,et al.  Functionalized large pore mesoporous silica nanoparticles for gene delivery featuring controlled release and co-delivery. , 2014, Journal of materials chemistry. B.

[35]  M. Tirrell,et al.  Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists , 2010, Expert review of vaccines.

[36]  Darrell J Irvine,et al.  Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.

[37]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[38]  Yue Zhang,et al.  An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. , 2006, International immunology.

[39]  C. Zhi,et al.  Chitosan-coated boron nitride nanospheres enhance delivery of CpG oligodeoxynucleotides and induction of cytokines , 2013, International journal of nanomedicine.

[40]  R. Kroczek,et al.  Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells , 2014, Mucosal Immunology.

[41]  J. Whittum-Hudson,et al.  Biomimetic design in microparticulate vaccines. , 2003, Biomaterials.

[42]  R. Langer,et al.  Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release , 2014, Vaccine.

[43]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[44]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[45]  C Jeffrey Brinker,et al.  Silica nanoparticle supported lipid bilayers for gene delivery. , 2009, Chemical communications.

[46]  T. Ohno,et al.  Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. , 2016, Angewandte Chemie.

[47]  Ronnie H. Fang,et al.  Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. , 2015, Nano letters.

[48]  S. Fuchs,et al.  Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity1 , 2008, The Journal of Immunology.

[49]  J. Ramsey,et al.  The role of the lymphatic system in vaccine trafficking and immune response. , 2011, Advanced drug delivery reviews.

[50]  Seungpyo Hong,et al.  Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. , 2006, Bioconjugate chemistry.

[51]  P. Pumpens,et al.  Silica Nanoparticles as the Adjuvant for the Immunisation of Mice Using Hepatitis B Core Virus-Like Particles , 2014, PloS one.

[52]  G. Weiner,et al.  Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Linlin Li,et al.  Silica nanorattle with enhanced protein loading: a potential vaccine adjuvant. , 2013, Journal of colloid and interface science.

[54]  J. Y. Scheerlinck,et al.  Virus-sized vaccine delivery systems. , 2008, Drug discovery today.

[55]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[56]  A. Krieg.  CpG motifs: the active ingredient in bacterial extracts? , 2003, Nature Medicine.

[57]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .